Acupuncture as Adjuvant Therapy for Glaucoma: Protocol for a Randomized Controlled Trial
JMIR Research Protocols · 2024
DOI: 10.2196/57888 ↗At a glance
Randomisierte kontrollierte Studie in JMIR Research Protocols, 2024. Written by Yi-Fang Liao and 3 co-authors. Institution: Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan. Major MEDLINE topics: Acupuncture Therapy. Cited 5 times so far (Crossref); 32 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Glaucoma is a chronic progressive optic neuropathy that necessitates lifelong treatment to reduce the decline of the optic nerve. Due to the extended and continuous treatments required for patients, complementary therapies are often considered alongside conventional treatments to enhance the effectiveness of the treatment. Acupuncture has demonstrated the potential to lower intraocular pressure in previous clinical trials, making it a promising glaucoma intervention.
Objective
The primary objective of this study is to conduct a single-center randomized control trial involving patients with glaucoma. Acupuncture will be evaluated as an adjunctive therapy. The trial aims to explore its effectiveness for glaucoma.
Methods
In this single-center randomized controlled trial, participants (N=50) with primary open-angle glaucoma will be randomly assigned to the treatment group, receiving ophthalmic acupuncture with “De Qi” sensation, or the control group, receiving minimum acupuncture stimulation on nonophthalmic acupoints. The intervention will consist of weekly acupuncture treatments for a total of 6 sessions. Participants will be assessed at 8 time points, which are baseline, during the intervention (6 times), and at a 3-month follow-up. The primary outcome measure is a change in the intraocular pressure before and after each acupuncture treatment. Secondary outcomes will include measurements of heart rate and blood pressure before and after acupuncture, best-corrected visual acuity, visual field, optical coherence tomography, optical coherence tomography angiography, the Glaucoma Symptom Scale, and the Glaucoma Quality of Life-15 questionnaire.
Results
Recruitment of participants for the trial commenced on June 28, 2023. A total of 10 participants have been enrolled to test the feasibility of the experiment. We anticipate that the preliminary data from this trial will be completed by December 2025.
Conclusions
This trial uses rigorous methodology and comprehensive outcome measurements to assess the clinical efficacy of acupuncture as an adjunctive therapy for glaucoma, providing valuable insights for future clinical treatment guidelines. Trial Registration ClinicalTrials.gov NCT05753137; https://clinicaltrials.gov/study/NCT05753137 International Registered Report Identifier (IRRID) DERR1-10.2196/57888
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan.
- Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
- Department of Ophthalmology, Eye Center, China Medical University Hospital, Taichung, Taiwan.
- School of Chinese Medicine, China Medical University, Taichung, Taiwan.
- Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung, Taiwan.
ORCID profiles: Yi-Fang Liao, Yu-Chen Lee, Hui-Ju Lin, Yi-Ching Shao
Cite
APA
Liao, Y. F., Lee, Y. C., Lin, H. J., & Shao, Y. C. (2024). Acupuncture as Adjuvant Therapy for Glaucoma: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/57888
Vancouver
Liao YF, Lee YC, Lin HJ, Shao YC. Acupuncture as Adjuvant Therapy for Glaucoma: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 2024. doi:10.2196/57888
BibTeX
@article{Liao2024,
author = {Liao, Yi-Fang and Lee, Yu-Chen and Lin, Hui-Ju and Shao, Yi-Ching},
title = {Acupuncture as Adjuvant Therapy for Glaucoma: Protocol for a Randomized Controlled Trial},
journal = {JMIR Research Protocols},
year = {2024},
doi = {10.2196/57888}
}
EUVIMED